Verified Supplier LinkVerified Supplier Link
NAD+ Buyer's Guide
Research-use only
NAD+ Buffered vs Unbuffered: Which Format Should You Actually Order? (2026)
Most suppliers sell two NAD+ formats: buffered and unbuffered. The pH chemistry, injection comfort, and stability profile differ, but the marketing rarely explains either side cleanly. This is a buyer-side comparison — not a dosing guide.
Quick summary
- Most community researchers pick buffered NAD+ because it tends to sting less after reconstitution.
- Unbuffered NAD+ reconstituted in standard BAC water sits around pH 4 — acidic enough that most users report stinging at the injection site.
- Buffered NAD+ uses a pH stabilizer (most commonly Tris) to bring the solution closer to physiological pH and improve vial-stage stability.
- Direct head-to-head human RCT data on injection-site tolerability is limited; the strongest evidence is biochemical stability data from a 2024 NREL study, plus consistent community reports.
- Buffered NAD+ pH
- ~7.0-8.5 (closer to physiological)
- Unbuffered NAD+ pH (reconstituted)
- ~3-4 (acidic)
- Most common buffer used
- Tris (tromethamine) at pH ~8.5
- Stability advantage (43-day NREL data)
- >90% NAD+ retained in Tris vs faster degradation in phosphate/HEPES
- Regulatory status
- Both formats research-use only; not FDA-approved
Quick verdict
If you have a choice, buffered NAD+ is usually the more comfortable option. The pH sits closer to what your tissue expects, and the published stability data favors a Tris-buffered solution over standard BAC water reconstitution.
Unbuffered NAD+ is not bad — it is just chemically more acidic at typical research-use concentrations, which is what produces the burning that people describe in forums. It is often cheaper per milligram and works fine for researchers willing to inject very slowly and rotate sites.
Either way: the choice does not change the *molecule*. NAD+ is NAD+. The buffer changes how the solution behaves at the syringe and during storage, not the underlying biochemistry.
Research-use only
Neither buffered nor unbuffered injectable NAD+ is FDA-approved. Both are only available as compounded preparations or research-use-only products. This page is educational and is not medical advice.
NAD+ supplies
Use this as a simple shopping checklist after you choose buffered or unbuffered NAD+. It does not replace dose math, vial instructions, or sterile handling guidance.
Recommended Supply
PEPPAL applies to eligible supplier checkout links when supported by the supplier.
Verified Supplier LinkVerified Supplier Link
NAD+ (Unbuffered)
View UnbufferedInjection Supplies
Swabs
Sterile alcohol prep pads.
Syringes
U-100 insulin syringes.
Peptide storage case
Compact travel case.
Lockable peptide fridge
Secure peptide storage
disclosure: supply links may earn PepPal a commission at no cost to you.
What to buy first
Start with the NAD+ format, then add the sterile prep items needed to handle the vial cleanly.
NAD+ format
Most community researchers choose buffered NAD+ because it tends to sting less after reconstitution.
Syringes and swabs
Use fresh supplies each time. Do not reuse syringes or swabs.
Before you order
Check the product page instead of relying on the card alone.
Format
Look for buffered, Tris, pH-stabilized, or unbuffered language on the supplier page.
Testing
Match the COA to the exact product and batch where the supplier makes that available.
Storage
Plan fridge space before reconstitution and label the vial with the mix date.
For dose math, reconstitution volumes, and route-specific instructions, use the full NAD+ protocol instead of this shopping checklist.
What "buffered" actually means
A buffer is a chemical added to a solution to keep its pH stable. NAD+ in pure water is naturally acidic — when you reconstitute lyophilized NAD+ powder with standard bacteriostatic water (BAC water), the resulting solution sits around pH 3-4.
BAC water itself has a target pH near 5.7 per the USP monograph. NAD+ is acidic enough to pull that down further when dissolved at typical research-use concentrations like 100-200 mg/mL.
Buffered NAD+ ships with a pH stabilizer already mixed into the formulation. The most commonly disclosed buffer on supplier product pages is Tris (tromethamine, also called Trizma), targeting a pH of about 8.5. Tris is a well-established pharmaceutical excipient used in approved injection and infusion solutions, vaccines, and other parenteral products.
The result is a final reconstituted solution at, or near, physiological pH (the body sits around 7.4) instead of an acidic ~pH 4.
How buffer pH affects NAD+ stability
A 2024 NREL study (peer-reviewed via PMC) compared NAD+ stability across three common buffers — sodium phosphate, HEPES, and Tris — at 19°C and 25°C over 43 days. Tris won. The paper reported >90% NAD+ retained at 19°C and ~75% at 25°C in Tris, versus higher degradation rates in phosphate and HEPES. Phosphate-containing buffers in particular show specific acid-catalyzed degradation of NADH at lower pH.
In plain English: at the same temperature and time window, NAD+ in a Tris buffer at pH ~8.5 stays intact longer than NAD+ in less optimal conditions. That is a chemistry result, not a clinical-outcome result.
Buffered vs unbuffered: side by side
NAD+ formulation comparison (research-use context)
| Category | Buffered NAD+ | Unbuffered NAD+ |
|---|---|---|
| What's in the vial | Lyophilized NAD+ plus a buffer agent (commonly Tris) | Lyophilized NAD+ only |
| Reconstituted pH | ~7.0-8.5, closer to physiological | ~3-4, distinctly acidic |
| Reported injection-site comfort | Less stinging; community reports converge | Stinging/burning commonly reported, especially at higher concentrations |
| Vial stability (43-day NREL data) | Higher retention in Tris buffer | Faster pH-driven degradation if not stored ideally |
| Reconstitution | Same BAC water volume; concentration math is identical | Same BAC water volume; concentration math is identical |
| Price per mg | Often a small premium | Often the cheaper SKU at the same supplier |
| Availability | Listed by most major research-use suppliers | Listed by most major research-use suppliers; the historical default |
| Regulatory status | Research-use only; not FDA-approved | Research-use only; not FDA-approved |
The table shows what is reproducibly different between the two formats. Outcome differences (energy, recovery, longevity) are driven by NAD+ itself, not by the buffer.
Injection-site comfort: where the formats actually differ
Stinging and burning at the injection site is the single most-reported NAD+ tolerability complaint. The driver is mostly pH and partly injection rate.
Your tissue sits at roughly pH 7.4. Injecting a solution at pH 3-4 is a meaningful gap. Tissue can buffer small volumes of off-pH fluid quickly, but not painlessly. The same chemistry behind GHK-Cu sting (which is also acidic on reconstitution) applies here.
What changes the experience
- pH closer to neutral. Buffered NAD+ at ~pH 7-8.5 reduces the chemical-irritation component of sting.
- Slow injection. Pushing the plunger over 5-10 seconds (sometimes longer) lets surrounding tissue accommodate the volume and the pH shift.
- Lower concentration. Diluting to 50 mg/mL instead of 100-200 mg/mL gives the same dose at a smaller pH-shock-per-mL.
- Smaller per-injection dose. Splitting a 100 mg dose into two 50 mg doses across two sites typically stings less than a single bigger draw.
- Fresh, room-temperature solution. Cold liquid stings more on its own, separate from pH.
- Fresh site rotation. Repeatedly hitting the same spot creates inflammation that amplifies the sting from any solution.
Dosing details live on the protocol page
We deliberately don't repeat the SubQ titration schedule, vial reconstitution math, or supplies tables here — those live on the NAD+ dosing protocol. This blog is only about the buffered-vs-unbuffered choice.
Stability and storage: what the buffer actually buys you
The 43-day NREL stability comparison is the clearest published evidence we have. In Tris buffer at 19°C, both NAD+ and NADH retained >90% of starting material. The same compounds in sodium phosphate or HEPES buffers degraded faster.
Practical translation for a research-use buyer:
- A buffered, refrigerated reconstituted vial is more forgiving if you stretch the use window slightly past the typical 14-30 day refrigerated guidance.
- An unbuffered solution at acidic pH degrades faster, particularly if it warms up or sits at room temperature.
- Either way, both formats benefit from refrigeration at 2-8°C, light protection, and use within the manufacturer or pharmacy beyond-use date.
Note: a 2024 Nature Metabolism paper described how cells biologically buffer their internal NAD+ pools across compartments. That is a separate concept from the pharmaceutical buffer in your vial — same word, different chemistry. The cellular result does not transfer to a sourcing decision.
Why most suppliers sell both formats
Two reasons: pricing and history.
Unbuffered NAD+ has been the historical default. It is the simpler product to manufacture (just lyophilized NAD+ powder), and it has been on supplier catalogs the longest. Many existing customers reorder it from habit rather than active preference.
Buffered NAD+ is a more recently widespread format. Suppliers price it as a small premium because it requires a multi-component formulation and pH-controlled fill. Some research customers also prefer the buffered version because it lines up better with how NAD+ is used in published in-vitro biochemistry assays — not because of a clinical-outcome difference.
Suppliers carry both because both sell. The choice is buyer-side, and it is not the kind of decision that affects the molecule's downstream biology.
Who should choose what
Choose buffered NAD+ if...
You have reported stinging from prior unbuffered SubQ injections, you want a more forgiving stability window after reconstitution, or the price gap at your supplier is small.
Choose unbuffered NAD+ if...
You inject very slowly without comfort issues, you are price-sensitive, or your supplier only stocks one format and the discount is meaningful.
Either is fine if...
You're using IV NAD+ (slow infusion masks most pH-related sting on its own), you're doing low single-digit-mg pilot doses, or your tolerance has already been good on whichever format you have.
Talk to a clinician if...
You have specific tolerability concerns, you're stacking NAD+ with other compounds, or you have any of the contraindications described on the protocol page.
Should you buffer unbuffered NAD+ at home?
There are forum threads describing buffer-it-yourself techniques — usually adding small volumes of sterile sodium bicarbonate solution to titrate pH up. We are not going to walk through how to do this.
The reasons to be careful are not theoretical:
- Adding a second sterile fluid to a multi-dose vial introduces additional contamination risk every time you draw.
- Targeting pH with home strips and a U-100 syringe is not the same as a pharmacy formulation; over-shooting alkaline pH creates its own irritation and can degrade the molecule differently.
- Sodium bicarbonate has its own osmolarity profile; a hand-mixed solution is not osmotically matched the way a real Tris-buffered fill is.
- If comfort is the goal, buying the buffered SKU is cheaper than the small additional supplier premium suggests once you account for time, sterile bicarbonate, and pH strips.
Better path
Order the buffered SKU, or talk to a licensed clinician about a 503A/503B compounded buffered preparation if cost is a concern.
How to verify either format before ordering
The product label is not always explicit. "NAD+ 500 mg" by itself doesn't tell you the buffer status. Quick checks before checkout:
- 1
Read the product description
Look for words like "buffered," "Tris," "pH-stabilized," or a stated reconstituted pH on the supplier product page.
- 2
Check the COA
Some COAs list the buffer system or the formulation pH. If you can't find it, see the PepPal COA-reading guide.
- 3
Look at the included diluent
If the supplier ships a kit with sodium bicarbonate or specifies Tris-buffered diluent, that is buffered. If it ships with standard BAC water only, default to unbuffered.
- 4
Match the SKU on the supplier's filter
Most major suppliers tag products as "NAD+" and "NAD+ (Buffered)" or list both as separate line items. Filter to confirm.
- 5
Cross-check current Finnrick or Janoshik testing
Tests focus on identity and purity, not on buffer status, but a recent independent test of the SKU you are about to order is a quality signal regardless of format.
What we still need to verify
- Direct human comparative data: there is no published RCT directly comparing buffered vs unbuffered injectable NAD+ for tolerability or efficacy as of May 2026. Most evidence is benchtop chemistry plus reproducible community reports.
- Concentration-dependent sting: the relationship between final reconstituted concentration and reported pain has been described but not formally quantified for NAD+ specifically.
- Long-horizon storage at room temperature: the NREL study covers 43 days; longer storage data for a Tris-buffered injectable NAD+ formulation in a research-use kit is limited.
- Supplier-specific buffer composition: "buffered NAD+" can mean different exact buffer systems across suppliers. Tris is most common but not universal. Verify on the supplier's product page.
Frequently Asked Questions
What is the difference between buffered and unbuffered NAD+?
Both contain the same NAD+ molecule. Buffered NAD+ ships with a pH stabilizer (most often Tris) that brings the reconstituted solution closer to physiological pH (~7-8.5). Unbuffered NAD+ is just lyophilized NAD+ powder, which gives an acidic solution (~pH 3-4) when reconstituted in standard bacteriostatic water.
Does buffered NAD+ sting less?
Yes — community reports converge on this, and the chemistry supports it. Tissue sits at ~pH 7.4. Injecting a near-neutral buffered solution is gentler than injecting an acidic ~pH 4 solution. Slow injection over 5-10 seconds and site rotation also reduce sting.
What buffer is in buffered NAD+?
Most disclosed formulations use Tris (tromethamine) at around pH 8.5. Tris is a well-established pharmaceutical excipient used in approved injection and infusion solutions. Some suppliers may use other buffers — verify on the product page.
Is buffered NAD+ more stable than unbuffered?
A 2024 NREL stability study found Tris-buffered NAD+ retained >90% activity over 43 days at 19°C, with faster degradation in sodium phosphate and HEPES buffers. Both formats still benefit from refrigeration and use within the manufacturer or pharmacy beyond-use date.
Is buffered NAD+ stronger than unbuffered?
No. The molecule is identical. The buffer changes pH and stability, not the underlying biology of NAD+. Outcome reports are driven by NAD+ itself, not by the buffer.
Should I buffer unbuffered NAD+ at home with sodium bicarbonate?
We don't recommend it. Adding a second sterile fluid to a multi-dose vial introduces contamination risk, home pH strips are imprecise, and over-correcting alkaline can create its own irritation. Buying the buffered SKU is the safer path. See how to read peptide COAs for related verification steps.
Do you reconstitute buffered NAD+ differently?
No. The same BAC water volumes used for unbuffered vials apply. Concentration math is identical. For exact mg-to-unit conversions, use the PepPal calculator.
How do you actually dose NAD+ once you've picked a format?
Format choice doesn't change dosing math. Common research-planning SubQ ranges sit at 50-100 mg per injection 2-3x weekly, with route-specific protocols for IV, IM, oral NMN/NR, intranasal, and pen/pre-mixed formats. For full route-by-route dosing tables, reconstitution math by vial size, supplies-by-cycle planning, and titration schedules, see the full NAD+ dosing protocol.
Is buffered or unbuffered NAD+ FDA-approved?
Neither. As of May 2026, injectable NAD+ in either format is not FDA-approved as a therapeutic. It is available only as a compounded preparation through 503A/503B pharmacies or as a research-use-only product through grey-market suppliers.
Does the buffer choice affect IV NAD+?
Less than for SubQ. IV NAD+ is delivered slowly over 2-4 hours into a venous bolus, and most of the pH-related sting issues are dampened by dilution and slow rate. Most clinic IV protocols use buffered or pharmacy-prepared formulations regardless.
Where can I buy buffered NAD+?
Most major research-use suppliers list both formats. Verify the format on the product page before ordering. Compare current COA-verified suppliers in the PepPal supplier directory. Code PEPPAL applies on supported supplier checkouts.
Is this guide medical advice?
No. This page is an educational research-use comparison. Neither format is FDA-approved. Always consult a licensed clinician for personal medical decisions.
Preferred supplier
Peptide PartnersNeed peptides? Start with a verified supplier.
PepPal's recommended source with current discount access and established testing standards.
3rd-party testedResearch-grade supplierHigh purity batches
Sources and research notes
- 1. Schaefer Z, et al. Long-Term Stability of Nicotinamide Cofactors in Common Aqueous Buffers: Implications for Cell-Free Biocatalysis. ACS Synthetic Biology / NREL technical report (PMC11597533) (2024)
- 2. Priority Peptides product documentation NAD+ 500mg (Buffered): CAS 53-84-9, Tris buffer pH ~8.5 formulation specification. Priority Peptides product page (2026)
- 3. U.S. National Library of Medicine / DailyMed Bacteriostatic Water for Injection USP — pH 5.7 (range 4.5-7.0), 0.9% benzyl alcohol preservative. DailyMed (USP monograph) (2026)
- 4. Sigma-Aldrich / Merck Tris (tromethamine) buffer chemistry, pKa ~8.1 at 25°C, role as pharmaceutical excipient in injection and infusion solutions. Sigma-Aldrich technical reference (2026)
- 5. Subcellular NAD+ Buffering paper Subcellular NAD+ pools are interconnected and buffered by mitochondrial NAD+. Nature Metabolism (2024)
- 6. Olympia Pharmaceuticals NAD Dosage Chart: 100 mg/mL compounded NAD+ formulation reference (IV/IM/SubQ). Olympia Pharmaceuticals blog (2026)
- 7. Cleveland Clinic Health Library NAD (Nicotinamide Adenine Dinucleotide): function, anatomy, and clinical context. Cleveland Clinic (2026)
- 8. Yoshino J, Baur JA, Imai SI. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metabolism (2018)
- 9. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology (2021)